0001438133-25-000187
SEC filingRevenue grew 2% YoY to $249M in Q3 2025, driven by improved pricing; gross margin expanded to 54%.
For the third quarter of 2025, Tandem Diabetes Care reported total sales of $249.3 million, a 2.2% increase from $244.0 million in the same period last year. Gross profit rose to $134.3 million (54% margin) from $124.7 million (51% margin), driven by improved average selling prices and reduced non-manufacturing costs, partially offset by less favorable product mix. Operating loss narrowed to $22.9 million from $26.1 million, despite a $9.1 million increase in SG&A expenses for commercial investments and restructuring. Net loss improved to $21.2 million from $23.3 million, benefiting from a $4.0 million income tax benefit due to the One Big Beautiful Bill Act. Other expense, net included a $2.7 million loss on equity investments and $2.1 million interest expense.
In the United States, sales grew 2.3% to $175.6 million, driven by higher average selling prices across pumps and supplies. Pump shipments were approximately 20,000, slightly down from nearly 21,000 in Q3 2024. The Tandem Choice program contributed no revenue in 2025 (vs. $1.0 million in Q3 2024). Outside the United States, sales increased 1.8% to $73.6 million, supported by favorable foreign exchange and higher supply volumes, while pump shipments fell to roughly 9,000 from nearly 11,000 due to distributor destocking ahead of planned direct sales activities in 2026.
Management highlighted several strategic initiatives: expansion of a multi-channel managed care strategy in the U.S. (pharmacy benefit pathway for Tandem Mobi and t:slim X2 supplies), international commercial preparations including direct sales in select European countries beginning in 2026, and ongoing R&D pipeline progress (tubeless extended-wear infusion site, next-gen patch pump, fully closed loop technology). The company noted typical seasonality with higher pump shipments in the second half of the year and the impact of regulatory approvals and competitive dynamics. No specific financial guidance was provided, but management expects to fund ongoing operations with existing cash of $319.1 million and future product sales.
As of September 30, 2025, Tandem Diabetes Care held $91.9 million in cash and cash equivalents and $227.2 million in short-term investments, totaling $319.1 million in liquid assets. Total assets were $874.7 million, down from $967.7 million at year-end 2024, driven by a reduction in short-term investments and an increase in accumulated deficit. Total debt (net) stood at $309.6 million, consisting solely of the 1.50% Convertible Senior Notes due 2029 (principal $316.3 million, net of $6.7 million unamortized issuance costs). The 2025 Notes were fully repaid ($40.8 million) in Q2 2025. Stockholders' equity decreased to $133.0 million from $263.1 million, primarily due to a $204.1 million net loss in the first nine months of 2025. The company maintains a full valuation allowance against deferred tax assets.
Total undiscounted operating lease payments were $180.7 million, with $5.4 million due in the remainder of 2025, $43.2 million in 2026-2027, and $132.1 million thereafter. The weighted-average remaining lease term is 8.8 years. A $4.9 million standby letter of credit is outstanding for one lease. The company has a $53.9 million product warranty reserve ($32.5 million current, $21.4 million long-term). A $36.0 million settlement with Roche includes a $31.6 million liability (present value), with $8.0 million paid in Q2 2025 and four annual installments. A CHF 28.0 million ($35.9 million) accrued liability remains for the AMF Medical acquisition, due in October 2025.
No dividends were declared or paid. In Q1 2024, the company repurchased $30.0 million of common stock (1.1 million shares) concurrently with the 2029 Notes offering. No new buyback authorization was disclosed. Capital expenditures totaled $13.3 million for the nine months ended September 30, 2025 (1.8% of sales). Debt activity included the full repayment of the $40.8 million remaining 2025 Notes and the issuance of $316.3 million in 2029 Notes (net proceeds $306.8 million). The company also entered into capped call transactions costing $15.8 million to reduce potential dilution.
The company operates as a single reportable segment: Insulin Pumps and Supplies. For the nine months ended September 30, 2025, total sales were $724.4 million, with $496.5 million (68.5%) from the United States and $227.9 million (31.5%) from outside the U.S. By product, pump revenue was $324.1 million and supplies/other was $400.3 million. Distributors accounted for 61% of U.S. sales and the vast majority of international sales.
For the nine months ended September 30, 2025, Tandem Diabetes Care reported a net loss of $204.1 million, yet operating cash flow was a negative $19.5 million. The primary driver of the divergence was a $75.2 million acquired in-process R&D expense (non-cash) and significant working capital outflows: accounts receivable increased by $14.8 million, prepaid and other current assets rose by $12.1 million, and accounts payable/accrued expenses decreased by $3.6 million. These were partially offset by a $17.3 million inventory reduction and $72.3 million in stock-based compensation.
Capital expenditures of $13.3 million were moderate relative to the operating cash burn, resulting in negative free cash flow (CFO minus capex) of approximately -$32.8 million. The company did not return capital to shareholders via buybacks or dividends.
Investing activities provided $87.9 million, driven by net maturities of short-term investments ($200.6M proceeds vs $56.0M purchases). Financing activities used $46.0 million, primarily from $40.8 million in principal payments on convertible notes due 2025.
Overall, cash generation remains weak, with operating cash flow deteriorating sharply year-over-year (from +$13.5M to -$19.5M). The company relies on investment maturities and debt repayments to manage liquidity.